NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No potential equality issues raised at the scoping stage

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

Experts raised that the Intramuscular administration may be suited for people protected by equality legislation. No specific equality issues were considered but the committee noted the comments in the expert submissions that the route of administration may be suited to people protected by equality legislation.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other issued have been identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations do not make it difficult for any groups to access the technology.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No potential impact on people with disabilities.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No recommendations or explanations required.

7.	Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
NA	

Approved by Associate Director (name):Janet Robertson......

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable, the recommendations have not changed.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable, the recommendations have not changed.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable, the recommendations have not changed.

5.	Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
No	

Approved by Associate Director (name):Janet Robertson......

Date: 21 November 2017